Dr. Anthony (Tony) Holler is the former CEO and founder of ID Biomedical, acquired in 2015 by Glaxo Smith Kline for $1.7 billion, and former Chairman of Corriente Resources Inc., sold for approximately $700 million to CRCC-Tongguan Investment Co. Tony is the current Chairman of CRH Medical Corp., a publicly traded company and serves as Sunniva’s Chief Executive Officer. His expertise includes strategic planning, mergers and acquisitions, and financing, with a singular focus on increasing shareholder value.
As the former owner and CEO of Vida Wealth Management Bahamas, former investment advisor at Canaccord Wealth Management, and former partner at an Alberta brokerage firm managing capital in excess of $3 billion, Leith has a proven track record for success. He lends his expertise in corporate strategy, financing, and sourcing potential mergers and acquisitions as the company’s Chief Strategy Officer.
Former director of ID Biomedical and current director of CRH Medical. Also former senior corporate law partner of Borden Ladner Gervais LLP, one of Canada’s largest law firms, whose practice encompassed mergers and acquisitions as well as corporate and securities law with an emphasis on the legal requirements of public companies and their boards.
Daniel is the founder and CEO of NHS, which operates boutique cannabis clinics across Canada with thousands of patients and growing. The NHS focuses on fulfilling underserved patient needs and educating on the importance of access to a physician-approved environment. NHS is a medical-centric corporation offering quality patient care, superior service and improved quality of life for its patients. NHS is grower-agnostic, choosing the finest products available at the best possible price.
Founder of Barker Pacific Group, a firm of experienced real estate professionals active in the acquisition, development, construction management, and asset management of major commercial projects. Founded in 1983, the company specializes in the development and acquisition of institutional-quality office, industrial, and residential projects. As a developer, BPG has completed, developed, or redeveloped in excess of $2.5 billion in commercial projects. The company enjoys close relationships with major corporate and institutional partners who commend the Barker Pacific Group management team's commitment to excellence, entrepreneurial vision, business acumen, and personal integrity.
Norm Mayr is a recently retired (2016) Audit Partner having spent 38 years in public practice with KPMG. He was the Risk Management and Professional Practice Partner for the Greater Vancouver Area practice of KPMG for the most recent 18 years of his career. In this role, Norm was consulted regularly on complex financial reporting, accounting, audit, and securities issues. Norm has extensive experience in the mining, forestry, technology, retail and industrial markets sectors and he served as lead partner on many of KPMG’s largest multinational clients in these industries. He was a founding member of the CICA Accounting Standards Board, and a member of the Canadian Advisory Group to the International Accounting Standards Committee.
Luke Stanton is an attorney and founder of the Frontera Law Group, a leading firm in the state of California focused on issues related to medical cannabis, which represents a host of quality cannabis companies, brands, products and ancillary service providers. Luke is also a general partner at Skytree Capital Partners, a Nevada-based private equity firm focused on the legal cannabis space. He has been featured in Financial Times Magazine, the National Marijuana News, mg Magazine, Cannabis Industry Journal, MJINews, LEFAIR Magazine and Merry Jane, and has made speaking appearances at numerous cannabis and investment conferences, summits and events across the country.
Todd brings 30 years of senior executive experience in building health care companies from the ground up. With expertise in finance, intellectual property, strategy and leadership, Todd has been involved with several start-ups as either CEO or as an active investor/board member. In these positions, Todd has helped raise over $600 million in equity/debt capital and participated in several merger and acquisition transactions. Todd is currently the President and CEO of C3J Therapeutics, Inc., a Los Angeles-based biotechnology company where he has raised over $125 million in equity capital. Prior to joining C3J, Todd spent 11 years as President of ID Biomedical until its $1.7 billion acquisition by GlaxoSmithKline.